The Longevity Method launch sets a new benchmark in health and wellness, offering consumers solutions that enhance vitality and resilience through every stage of life. To learn more about Longevity ...

UPPSALA, SE / ACCESS Newswire / July 8, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB (publ.) invites investors, analysts, and media to a webcast presentation of the second quarter report for ...

The center will open on July 8, 2025 and will provide a suite of detox and residential addiction services.  SPRINGFIELD, MA / ACCESS Newswire / July 8, 2025 / In 2023, the State of Massachusetts ...

The global Allergy Diagnostics Market is valued at USD 5.99 billion in 2024 and is projected to reach a value of USD 13.48 ...

HATFIELD, HERTFORDSHIRE, UNITED KINGDOM (UK), and MAIDENHEAD, UK, 7 JULY 2025 – Eisai Europe Ltd. and Biogen Idec Ltd. announced today that the Scottish Medicines Consortium (SMC) has not recommended ...

DIADEME’ project awarded €6.5 million in government funding via France 2030, enabling Ciloa to advance development of its bio-drug APN-sEV (Adiponectin associated with exosomes), the world’s only ...

Inhaled Antifungals Market to Reach $450 Million by 2025, Fueled by Rising Adoption in Invasive Fungal Infections The global inhaled antifungals market is projected to reach $450 million in 2025, ...

MMJ-001 Marks a Pharmaceutical First in Cannabis Medicine with FDA-Grade Formulation for a Devastating Neurological Disorder while awaiting final FDA approval for use in clinical trials. WASHINGTON, D ...

ANGLE plc celebrates 100 peer-reviewed studies validating its Parsortix® system, enhancing cancer diagnostics and personalised treatment strategies.

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, ...

Responding to Dr Penny Dash’s review of patient safety across the health and care landscape, Matthew Taylor, chief executive of the NHS Confederation, said: “Patient empowerment is crucial to the ...

UCB’s continued commitment to leading research aimed at improving treatment outcomes for people living with neurological conditions.Data include the use of FINTEPLA®▼ (fenfluramine)1 in Dravet ...